Work

Real-world outcomes of induction chemoimmunotherapy in patients with non–small cell lung cancer who have never smoked

Year: 2026

Type: article

Abstract: Among patients with non–small cell lung cancer (NSCLC), smoking is associated with tumor and genomic features that may enhance response to chemoimmunotherapy. In contrast, exploratory subgroup analyses from recent clinical trials found that induction chemoimmunotherapy may be less effective among patients without a smoking history, although these investigations were not powered for this subgroup.1-5 Despite both the increasing incidence of NSCLC among patients who have never smoked and the growing use of perioperative chemoimmunotherapy, contemporary data describing outcomes within this population remain limited.

Source: JTCVS Open

DOI: 10.1016/j.xjon.2026.101983

Authors: Alison S. Baskin, Maureen Canavan, Benjamin J. Resio, Daniel J. Boffa, Giorgio Caturegli

Institutions: University of California, San Francisco, Yale University

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,431